Clarest launches Clarest Path, AI medication-risk platform for health plans

Clarest Health said Wednesday it launched the next generation of Clarest Path, a medication-intelligence platform that uses a real-time machine-learning engine to flag medication risk earlier for health plans and at-risk providers.

Health plans still buy one vendor per Star Ratings measure, while missed medicines keep driving avoidable cost. Clarest is putting a live risk model, pharmacists and nurses, and pharmacy fulfillment on one platform so the next step can happen before an emergency visit.

On Wednesday, 30 September 2026, Clarest Health announced the next generation of Clarest Path. Clarest calls itself a company for personalized medication management, the work of matching a person to the right medicines and helping that person stay on them. It calls Clarest Path a full-service medication intelligence platform. The platform combines an integrated data layer, one store of member information, with a predictive intervention engine, software that flags who needs a clinician to step in. It is built for health plans and at-risk providers. An at-risk provider, in that phrase, is a clinic or medical group that shares the cost when a patient gets sicker. Clarest says the platform is meant to find medication-related risk earlier, support Star performance, support better patient outcomes, and cut costs that come when a person does not take a medicine as prescribed. Star Ratings are Medicare’s quality scores for a health plan. Business Wire carries the release. The dateline is Vienna, Virginia. A Business Wire reprint stamps the release September 30, 2026, at 9:10 a.m. Eastern. Those lines are Clarest’s.

At the core, Clarest says, is a clinically validated, real-time machine-learning engine. Machine learning is software that finds patterns in data and keeps updating as new data arrives. Real-time, here, means the flag can move as the member’s record moves, rather than waiting on a report that is already old. Clarest says the engine continuously identifies and prioritizes risk across medication programs, so a care team can intervene before an adverse event, a harmful result tied to the medicines, or before an emergency response is needed. The premise Clarest prints is that good medication management means catching risk early, staying with a patient through every care transition, and pairing the software with clinical expertise. A care transition is a handoff, such as leaving the hospital for home. Clinically validated is Clarest’s phrase for the engine. Those lines are Clarest’s.

Clarest says the one platform covers five medication-related Star Ratings measures: CMR, Adherence, SUPD, COB, and Poly-ACh. In Medicare, those labels usually mean the following. CMR is a comprehensive medication review, a full look at what a member takes. The related score is how many eligible members in a medication-therapy program received one. Adherence is whether members keep taking prescribed medicines. Medicare tracks that separately for diabetes drugs, blood-pressure drugs, and cholesterol drugs. Clarest lists Adherence as one of the five. SUPD is statin use in persons with diabetes. A statin is a cholesterol drug. COB is concurrent use of opioids and benzodiazepines, a strong pain medicine and a drug used for anxiety or sleep, taken across the same stretch of days. Poly-ACh is polypharmacy with anticholinergic drugs in older adults: several medicines that block a nerve-and-muscle chemical, taken together. Polypharmacy means many medicines at once. Clarest uses those five labels. It also says the same platform is meant to cut avoidable use of care and improve member outcomes. Those aims are Clarest’s.

Clarest says health plans can no longer rely on disconnected tools that treat risk as a static score passed from one vendor to the next. A static score is a number that sits still after it is calculated. Clarest says that split leaves avoidable medical cost on the table. Clarest Path is built to close the gap with one platform that keeps taking in data and turns scattered member contacts into one care journey, worked with the patient’s own providers. Clarest says fewer, more connected contacts can cover more than one quality need, help manage what the plan spends on drugs, cut the total cost of care, and put pharmacy and quality teams at the center. Those lines are Clarest’s.

Hammad Shah, chief executive of Clarest Health, said the rules around Star Ratings may still be evolving, but good medication management has not changed: catch risk early, stay with the patient, and follow through. He said that bringing all medication-related measures under one roof removes the confusion of siloed point solutions and replaces them with continuous, personalized care that protects member outcomes and plan performance. A point solution, here, is a tool built for one measure. That quotation is his, in the release.

The release cites a case study. Clarest says it recently ran a fully integrated medication therapy management and adherence program across two Medicare Part D contracts. Medication therapy management, which the release shortens to MTM, is Medicare’s program for reviewing a member’s medicines. Part D is the Medicare drug benefit. Clarest says the results include an estimated $55 decrease in monthly cost per engaged member. An engaged member, here, is a member who took part in the program. Fifty-five dollars a month is about $660 over a year, if that monthly drop held for twelve months. Clarest also cites $3.8 million in combined program value, a return of about 6.9 times the plan’s investment in 2025. A 6.9 times return means about $6.90 back for each dollar spent, on Clarest’s arithmetic. The CMR completion rate ran 25.6 percent ahead of the prior-year pace, meaning reviews were being finished faster than at the same point the year before. The release does not say whether 25.6 percent is a relative rise or extra percentage points. It does not name the plan. These figures are Clarest’s, from the case study in the release. The release does not say an outside auditor checked them.

Clarest sets the product against tools that only produce a report. It says Clarest Path is built around a real-time engine that sorts and prioritizes risk across every program and drives the interventions, the steps a clinician takes, before cost and outcomes get worse. The platform uses Clarest’s nationwide set of long-term care and at-home pharmacies, so a health plan or a provider can follow a patient from a facility to home and back. Those lines are Clarest’s.

Five capabilities, as the release lists them. Real-time risk intelligence: an engine trained on more than 10 years of data that keeps finding emerging risk and builds the care plan, rather than handing off a score. Workflow unification: one platform for CMR, Adherence, SUPD, COB, and Poly-ACh, plus coordination with providers and personalized fulfillment, the work of getting the medicine to the person. AI-guided clinical interventions: a library of 3,000 recommendations curated by pharmacists and clinicians. Curated means a clinician chose and kept them. The library is supposed to give nurses, pharmacists, and other care-team members real-time scripting, dynamic recommendations, and AI-powered patient summaries. Scripting, here, is suggested wording for a call. A summary is a short read of the patient, so the clinician spends less time digging through the chart. Patient and provider engagement: automation with a person still in the loop, for a refill problem, a medicine change, or a barrier to picking a prescription up, closed through electronic links across the health system. Closed-loop fulfillment: Clarest’s own pharmacies, meant to close adherence gaps for people aging at home, including people on complex regimens. Those lines are Clarest’s. The release does not print a price.

The product page on clarest.com describes the same platform. It says a real-time machine-learning engine, trained and supervised by pharmacists, surfaces member risk so nurses and pharmacists can intervene. It says the platform is HIPAA-compliant and lined up with CMS standards. HIPAA is the U.S. health-privacy law. CMS is the agency that runs Medicare. The page says a clinical team of more than 600 nurses and pharmacists does the human side of each outreach. That figure is the page’s count of the clinical team. It is not a headcount hired for this announcement. The page says live guidance gives call-center nurses and pharmacists real-time scripting and patient summaries. It says the security frame is SOC 2 Type 2 certified and fully HIPAA compliant. SOC 2 Type 2 is an outside audit of how a company protects data over a period of time. The page also says a nationwide pharmacy network supports members aging at home and members with heavy medication loads. Those lines are on the product page. The page does not print a price, and it does not name a health-plan customer. It describes a software platform and a clinical service. It does not describe a device clearance.

In plain terms, Clarest said on Wednesday that health plans and at-risk providers can use one platform for five Medicare medication measures. A machine-learning engine keeps re-ranking risk. Nurses and pharmacists act on that list. Pharmacies can fill the prescription. The $55 a month, the $3.8 million, the 6.9 times return, and the 25.6 percent CMR pace are Clarest’s case-study figures for two unnamed Medicare Part D contracts. The release does not name a customer, and it does not print a price.

The picture is Clarest’s Clarest Path clinical screen, from the product page, shown on a monitor with a teal margin. The chart on the screen lists a patient named Donna Adams, age 77, on Medicare Part D, with a Critical risk flag. The interventions name a concurrent opioid and benzodiazepine pair, in use for more than 30 days, and an FDA boxed warning that using them together raises the risk of slowed breathing, overdose, and death. They also flag polypharmacy: ten medications and a significant anticholinergic burden, with Totropium, oxybutynin, amitriptyline, and diphenhydramine named on the screen. A third block flags home delivery and medication education, including pill packs after a hospital discharge. An overlay titled Medication Review is a post-discharge reconciliation for that chart. It marks the admission and the patient as high risk, and one section as verified. A line on the overlay says the information was gathered with the help of AI. It is the product screen. It is not a named health-plan customer, and the dates on the chart are not the dateline of this launch.